Posted by Michael Wonder on 29 Feb 2020
Melanoma medicine added to the Pharmaceutical Benefits Scheme
29 February 2020 - A host of melanoma treatments have been added to the Pharmaceutical Benefits Scheme, slashing costs for patients who have been forking out more than $100,000.
From today the Morrison government has added a host of Opdivo (nivolumab) treatments to the Pharmaceutical Benefits Scheme.
The changes will directly impact more than 2,000 people who are undergoing immunotherapy treatment, as well many more who are yet to be diagnosed.
